Epic Opioid Risk Score: Validation Study Raises Concerns

A recently published validation study casts doubt on the accuracy of Epic’s Opioid Risk Score (ORS), a tool widely used in primary care settings to identify patients potentially at risk of opioid misuse or overdose. The findings, published in the Journal of General Internal Medicine on February 17, 2026, suggest the score demonstrates excellent ability to distinguish between patients who will and won’t experience opioid-related events, but struggles to reliably identify those actually at risk.

How the Epic Opioid Risk Score Works

The Epic ORS is a cognitive computing model integrated into electronic health records (EHRs). It aims to help clinicians assess a patient’s risk before prescribing opioids, a class of drugs with a high potential for addiction and overdose. The score is calculated using data already present in the EHR, offering a seemingly efficient way to flag patients who might benefit from closer monitoring or alternative pain management strategies. The tool is intended to increase treatment rates for opioid use disorder (OUD) by proactively identifying individuals who may demand intervention. More information about the tool can be found on MDCalc.

Study Details and Findings

Researchers conducted a prospective cohort study across three large integrated health systems, analyzing data from over 704,000 patients aged 18-75 who had a primary care visit between April 2021 and December 2022. The study focused on patients without a pre-existing diagnosis of opioid use disorder. The primary outcome measured was a new diagnosis of OUD or an opioid overdose within 12 months of the initial risk score calculation.

The results revealed that the vast majority of patients (99.6%) were classified as low risk by the ORS. However, only a small fraction of patients (0.3%) actually received an OUD diagnosis or experienced an overdose during the follow-up period. While the model demonstrated strong discrimination – meaning it could effectively differentiate between those who did and did not experience an event (c-statistic = 0.815) – its sensitivity was low (0.0783, 95% CI 0.0675, 0.0892). Which means it correctly identified only about 8% of patients who went on to develop OUD or overdose. Specificity was high (0.9965, 95% CI 0.9963, 0.9966), indicating it rarely flagged patients who were *not* at risk. However, the positive predictive value (PPV) was also low (0.0694, 95% CI 0.0598, 0.0791), meaning that even among those identified as high risk, most did not actually experience an adverse event.

Perhaps most concerning, the study found the model was “poorly calibrated,” consistently underestimating risk for patients who ultimately experienced OUD or overdose. This suggests clinicians relying on the score might be lulled into a false sense of security.

What Does This Mean for Patients and Clinicians?

The study’s findings do not suggest the Epic ORS is entirely useless. Its high specificity means it can be helpful in ruling *out* risk in many patients. However, the low sensitivity and poor calibration raise significant concerns about its ability to reliably identify those who truly need intervention. Clinicians should not rely solely on the ORS when making decisions about opioid prescriptions. A comprehensive assessment, including a thorough patient history, consideration of individual risk factors, and open communication with the patient, remains crucial.

It’s vital to understand the difference between sensitivity and specificity. Sensitivity refers to the ability of a test to correctly identify those *with* a condition, while specificity refers to its ability to correctly identify those *without* the condition. A test with high specificity minimizes false positives, but a test with low sensitivity can miss a significant number of true positives. In the context of opioid risk, missing true positives – patients who are actually at risk – can have serious consequences.

The Broader Context of Opioid Risk Assessment

The Epic ORS is just one of several tools available to assess opioid risk. The Opioid Risk Tool (ORT), for example, is another commonly used assessment. However, even these tools have limitations. Many risk assessment tools rely on self-reported data, which can be subject to bias. Risk factors for opioid misuse are complex and multifaceted, and no single tool can capture the full picture.

The ongoing opioid crisis underscores the need for effective risk assessment and prevention strategies. According to the Centers for Disease Control and Prevention (CDC), over 150 people die every day from overdoses involving synthetic opioids like fentanyl. CDC data highlights the urgent need for improved strategies to prevent opioid misuse and overdose.

Limitations of the Validation Study

The researchers acknowledge several limitations to their study. The data were drawn from three large health systems, which may not be representative of all patient populations. The study also focused on patients initiating opioid therapy in primary care, and the findings may not generalize to other settings, such as emergency departments or pain clinics. The study only examined outcomes within 12 months of the initial risk score calculation, and some patients developed OUD or experienced an overdose after this period.

What Comes Next: Refining Risk Prediction

The authors of the study suggest that further research is needed to improve the accuracy and calibration of opioid risk prediction models. This includes exploring new data sources, refining existing algorithms, and developing more personalized risk assessments. The findings also highlight the importance of ongoing monitoring and evaluation of risk prediction tools in real-world clinical settings. Epic has not yet released a statement regarding the study’s findings, but This proves likely they will review their model in light of this new evidence. Continued external validation, like the study published in the Journal of General Internal Medicine, is essential to ensure these tools are used safely and effectively.